{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:42:39Z","timestamp":1780454559245,"version":"3.54.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s11894-023-00863-y","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T18:41:13Z","timestamp":1675881673000},"page":"45-51","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Mild Crohn\u2019s Disease: Definition and Management"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4701-427X","authenticated-orcid":false,"given":"Jennifer","family":"Claytor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushkar","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin N.","family":"Ananthakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Frederic","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasi","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan C.","family":"Ungaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,8]]},"reference":[{"key":"863_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","volume":"113","author":"GR Lichtenstein","year":"2018","unstructured":"\u2022\u2022 Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn\u2019s Disease in Adults. Am J Gastroenterol. 2018;113:481\u2013517. These revised guidelines incorporate recent evidence against the previously prevalent role of mesalamines and antibiotics in the treatment of mild-to-moderate Crohn's Disease, excluding higher-risk patients with perianal disease who do require antibiotic therapy. Close monitoring with symptomatic management is described as a reasonable alternative for patients after induction of remission.","journal-title":"Am J Gastroenterol."},{"key":"863_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/j.gastro.2021.04.063","volume":"161","author":"M Agrawal","year":"2021","unstructured":"Agrawal M, Spencer EA, Colombel J-F, Ungaro RC. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User\u2019s Guide for Adult and Pediatric Gastroenterologists. Gastroenterology. 2021;161:47\u201365.","journal-title":"Gastroenterology"},{"key":"863_CR3","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/ibd\/izab074","volume":"28","author":"S Singh","year":"2021","unstructured":"Singh S, Qian AS, Nguyen NH, Ho SKM, Luo J, Jairath V, et al. Trends in U. S. Health Care Spending on Inflammatory Bowel Diseases, 1996\u20132016. Inflamm Bowel Dis. 2021;28:364\u201372.","journal-title":"Inflamm Bowel Dis."},{"key":"863_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11894-016-0523-z","volume":"18","author":"FI Scott","year":"2016","unstructured":"Scott FI, Lichtenstein GR. Approach to the Patient with Mild Crohn\u2019s Disease: a 2016 Update. Curr Gastroenterol Rep. 2016;18:50.","journal-title":"Curr Gastroenterol Rep"},{"key":"863_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","volume":"11","author":"F Gomoll\u00f3n","year":"2017","unstructured":"Gomoll\u00f3n F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn\u2019s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017;11:3\u201325.","journal-title":"J Crohns Colitis"},{"key":"863_CR6","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","volume":"160","author":"JD Feuerstein","year":"2021","unstructured":"Feuerstein JD, Ho EY, Shmidt E, Singh H, Falck-Ytter Y, Sultan S, et al. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn\u2019s Disease. Gastroenterology Elsevier. 2021;160:2496\u2013508.","journal-title":"Gastroenterology Elsevier"},{"key":"863_CR7","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","volume":"390","author":"J-F Colombel","year":"2017","unstructured":"Colombel J-F, Panaccione R, Bossuyt P, Lukas M, Baert F, Va\u0148\u00e1sek T, et al. Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet Lond Engl. 2017;390:2779\u201389.","journal-title":"Lancet Lond Engl"},{"key":"863_CR8","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3109\/00365521.2015.1128965","volume":"51","author":"C Reenaers","year":"2016","unstructured":"Reenaers C, Pirard C, Vankemseke C, Latour P, Belaiche J, Louis E. Long-term evolution and predictive factors of mild inflammatory bowel disease. Scand J Gastroenterol Taylor & Francis. 2016;51:712\u20139.","journal-title":"Scand J Gastroenterol Taylor & Francis"},{"key":"863_CR9","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.gastrohep.2013.07.004","volume":"36","author":"Y Zabana","year":"2013","unstructured":"Zabana Y, Garcia-Planella E, van Domselaar M, Ma\u00f1osa M, Gordillo J, L\u00f3pez-Sanrom\u00e1n A, et al. Predictors of favourable outcome in inflammatory Crohn\u2019s disease A retrospective observational study. Gastroenterol Hepatol. 2013;36:616\u201323.","journal-title":"Gastroenterol Hepatol"},{"key":"863_CR10","first-page":"1140","volume":"61","author":"J Cosnes","year":"2012","unstructured":"Cosnes J, Bourrier A, Nion-Larmurier I, Sokol H, Beaugerie L, Seksik P. Factors affecting outcomes in Crohn\u2019s disease over 15 years. Gut BMJ Publishing Group. 2012;61:1140\u20135.","journal-title":"Gut BMJ Publishing Group"},{"key":"863_CR11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3109\/00365529509096316","volume":"30","author":"P Munkholm","year":"1995","unstructured":"Munkholm P, Langholz E, Davidsen M, Binder V. Disease Activity Courses in a Regional Cohort of Crohn\u2019s Disease Patients. Scand J Gastroenterol Taylor & Francis. 1995;30:699\u2013706.","journal-title":"Scand J Gastroenterol Taylor & Francis"},{"key":"863_CR12","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1093\/ecco-jcc\/jjab030","volume":"15","author":"M Agrawal","year":"2021","unstructured":"Agrawal M, Miranda MB, Walsh S, Narula N, Colombel J-F, Ungaro RC. Prevalence and Progression of Incidental Terminal Ileitis on Non-diagnostic Colonoscopy: A Systematic Review and Meta-analysis. J Crohns Colitis. 2021;15:1455\u201363.","journal-title":"J Crohns Colitis."},{"key":"863_CR13","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1111\/j.1365-2036.2008.03681.x","volume":"27","author":"F Tin\u00e8","year":"2008","unstructured":"Tin\u00e8 F, Rossi F, Sferrazza A, Orlando A, Mocciaro F, Scimeca D, et al. Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn\u2019s disease. Aliment Pharmacol Ther. 2008;27:1210\u201323.","journal-title":"Aliment Pharmacol Ther"},{"key":"863_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1053\/gast.2001.26279","volume":"121","author":"WA Faubion","year":"2001","unstructured":"Faubion WA, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255\u201360.","journal-title":"Gastroenterology"},{"key":"863_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1365-2036.2006.02974.x","volume":"24","author":"G-T Ho","year":"2006","unstructured":"Ho G-T, Chiam P, Drummond H, Loane J, Arnott IDR, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006;24:319\u201330.","journal-title":"Aliment Pharmacol Ther"},{"key":"863_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"\u2022\u2022 Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Medical Treatment. J Crohns Colitis. 2020;14:4\u201322. The ECCO guidelines focus on features predicting a low 5-year risk of disease progression within their definition of mild disease. These guidelines include ileocolonic location and ever being treated with systemic steroids. No maintenance treatment is also endorsed as an option for some low-risk patients.","journal-title":"J Crohns Colitis"},{"key":"863_CR17","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJM199409293311303","volume":"331","author":"GR Greenberg","year":"1994","unstructured":"Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, et al. Oral budesonide for active Crohn\u2019s disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med. 1994;331:836\u201341.","journal-title":"N Engl J Med."},{"key":"863_CR18","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1111\/j.1572-0241.2002.05835.x","volume":"97","author":"WJ Tremaine","year":"2002","unstructured":"Tremaine WJ, Hanauer SB, Katz S, Winston BD, Levine JG, Persson T, et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn\u2019s disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol. 2002;97:1748\u201354.","journal-title":"Am J Gastroenterol"},{"key":"863_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.crohns.2012.06.006","volume":"7","author":"Y Suzuki","year":"2013","unstructured":"Suzuki Y, Motoya S, Takazoe M, Kosaka T, Date M, Nii M, et al. Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn\u2019s disease: a multicentre, double-blind, randomized, parallel-group Phase II study. J Crohns Colitis. 2013;7:239\u201347.","journal-title":"J Crohns Colitis"},{"key":"863_CR20","doi-asserted-by":"crossref","unstructured":"Rezaie A, Kuenzig ME, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH, et al. Budesonide for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2015;CD000296.","DOI":"10.1002\/14651858.CD000296.pub4"},{"key":"863_CR21","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1177\/2050640620945949","volume":"8","author":"J Burisch","year":"2020","unstructured":"Burisch J, Bergemalm D, Halfvarson J, Domislovic V, Krznaric Z, Goldis A, et al. The use of 5-aminosalicylate for patients with Crohn\u2019s disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study. United Eur Gastroenterol J. 2020;8:949\u201360.","journal-title":"United Eur Gastroenterol J"},{"key":"863_CR22","first-page":"CD008870","volume":"7","author":"W-C Lim","year":"2016","unstructured":"Lim W-C, Wang Y, MacDonald JK, Hanauer S. Aminosalicylates for induction of remission or response in Crohn\u2019s disease. Cochrane Database Syst Rev. 2016;7:CD008870.","journal-title":"Cochrane Database Syst Rev."},{"key":"863_CR23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1053\/j.gastro.2010.11.004","volume":"140","author":"A Tromm","year":"2011","unstructured":"Tromm A, Bungani\u010d I, Tomsov\u00e1 E, Tulassay Z, Luk\u00e1\u0161 M, Kykal J, et al. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn\u2019s disease. Gastroenterology. 2011;140:425-434.e1. quiz e13-14.","journal-title":"Gastroenterology."},{"key":"863_CR24","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1056\/NEJM199808063390603","volume":"339","author":"OO Thomsen","year":"1998","unstructured":"Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, et al. A comparison of budesonide and mesalamine for active Crohn\u2019s disease. International Budesonide-Mesalamine Study Group. N Engl J Med. 1998;339:370\u20134.","journal-title":"N Engl J Med."},{"key":"863_CR25","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1056\/NEJM197309202891209","volume":"289","author":"P Goldman","year":"1973","unstructured":"Goldman P. Therapeutic Implications of the Intestinal Microflora. N Engl J Med. 1973;289:623\u20138.","journal-title":"N Engl J Med."},{"key":"863_CR26","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199502023320503","volume":"332","author":"BG Feagan","year":"1995","unstructured":"Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, et al. Methotrexate for the treatment of Crohn\u2019s disease. The North American Crohn\u2019s Study Group Investigators. N Engl J Med. 1995;332:292\u20137.","journal-title":"N Engl J Med."},{"key":"863_CR27","doi-asserted-by":"crossref","unstructured":"Chande N, Patton PH, Tsoulis DJ, Thomas BS, MacDonald JK. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2015;CD000067.","DOI":"10.1002\/14651858.CD000067.pub3"},{"key":"863_CR28","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/ibd.20777","volume":"15","author":"GJ Mantzaris","year":"2009","unstructured":"Mantzaris GJ, Christidou A, Sfakianakis M, Roussos A, Koilakou S, Petraki K, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn\u2019s disease. Inflamm Bowel Dis. 2009;15:375\u201382.","journal-title":"Inflamm Bowel Dis"},{"key":"863_CR29","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2017.16071","volume":"318","author":"M Lemaitre","year":"2017","unstructured":"Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, et al. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. JAMA. 2017;318:1679\u201386.","journal-title":"JAMA"},{"key":"863_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40168-020-0792-5","volume":"8","author":"H Sokol","year":"2020","unstructured":"Sokol H, Landman C, Seksik P, Berard L, Montil M, Nion-Larmurier I, et al. Fecal microbiota transplantation to maintain remission in Crohn\u2019s disease: a pilot randomized controlled study. Microbiome. 2020;8:12.","journal-title":"Microbiome"},{"key":"863_CR31","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1177\/2050640619845986","volume":"7","author":"L Gutin","year":"2019","unstructured":"Gutin L, Piceno Y, Fadrosh D, Lynch K, Zydek M, Kassam Z, et al. Fecal microbiota transplant for Crohn disease: A study evaluating safety, efficacy, and microbiome profile. United Eur Gastroenterol J. 2019;7:807\u201314.","journal-title":"United Eur Gastroenterol J"},{"key":"863_CR32","first-page":"CD006634","volume":"7","author":"BN Limketkai","year":"2020","unstructured":"Limketkai BN, Akobeng AK, Gordon M, Adepoju AA. Probiotics for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2020;7:CD006634.","journal-title":"Cochrane Database Syst Rev."},{"key":"863_CR33","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1007\/s10620-020-06477-y","volume":"66","author":"JM Rhodes","year":"2021","unstructured":"Rhodes JM, Subramanian S, Flanagan PK, Horgan GW, Martin K, Mansfield J, et al. Randomized Trial of Ciprofloxacin Doxycycline and Hydroxychloroquine Versus Budesonide in Active Crohn\u2019s Disease. Dig Dis Sci. 2021;66:2700\u201311.","journal-title":"Dig Dis Sci"},{"key":"863_CR34","first-page":"CD012730","volume":"2","author":"CM Townsend","year":"2019","unstructured":"Townsend CM, Parker CE, MacDonald JK, Nguyen TM, Jairath V, Feagan BG, et al. Antibiotics for induction and maintenance of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2019;2:CD012730.","journal-title":"Cochrane Database Syst Rev."},{"key":"863_CR35","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1053\/j.gastro.2011.11.032","volume":"142","author":"C Prantera","year":"2012","unstructured":"Prantera C, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P, et al. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn\u2019s disease. Gastroenterology. 2012;142:473-481.e4.","journal-title":"Gastroenterology"},{"key":"863_CR36","first-page":"CD010410","volume":"2018","author":"CE Parker","year":"2018","unstructured":"Parker CE, Nguyen TM, Segal D, MacDonald JK, Chande N. Low dose naltrexone for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2018;2018:CD010410.","journal-title":"Cochrane Database Syst Rev."},{"key":"863_CR37","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/ecco-jcc\/jjab069","volume":"15","author":"T Naftali","year":"2021","unstructured":"Naftali T, Bar-Lev Schleider L, Almog S, Meiri D, Konikoff FM. Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn\u2019s Disease, a Randomised Controlled Trial. J Crohns Colitis. 2021;15:1799\u2013806.","journal-title":"J Crohns Colitis"},{"key":"863_CR38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005176-200007000-00005","volume":"31","author":"RB Heuschkel","year":"2000","unstructured":"Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrition and corticosteroids in the treatment of acute Crohn\u2019s disease in children. J Pediatr Gastroenterol Nutr. 2000;31:8\u201315.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"863_CR39","first-page":"752","volume":"19","author":"R Sigall Boneh","year":"2021","unstructured":"Sigall Boneh R, Van Limbergen J, Wine E, Assa A, Shaoul R, Milman P, et al. Dietary Therapies Induce Rapid Response and Remission in Pediatric Patients With Active Crohn\u2019s Disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2021;19:752\u20139.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"863_CR40","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1053\/j.gastro.2019.04.021","volume":"157","author":"A Levine","year":"2019","unstructured":"Levine A, Wine E, Assa A, Sigall Boneh R, Shaoul R, Kori M, et al. Crohn\u2019s Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial. Gastroenterology. 2019;157:440-450.e8.","journal-title":"Gastroenterology"},{"key":"863_CR41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S2468-1253(21)00299-5","volume":"7","author":"H Yanai","year":"2022","unstructured":"\u2022 Yanai H, Levine A, Hirsch A, Boneh RS, Kopylov U, Eran HB, et al. The Crohn\u2019s disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn\u2019s disease (CDED-AD): an open-label, pilot, randomised trial. Lancet Gastroenterol Hepatol Elsevier. 2022;7:49\u201359. Enteral nutrition has been widely recommended as an induction and maintenance strategy for pediatric patients, but issues with interest and long-term adherence have limited implementation in adults. However, for motivated patients, the CDED may represent an effective option with a favorable safety profile. Further real-life implementation studies are needed.","journal-title":"Lancet Gastroenterol Hepatol. Elsevier"},{"key":"863_CR42","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1053\/j.gastro.2021.05.047","volume":"161","author":"JD Lewis","year":"2021","unstructured":"Lewis JD, Sandler RS, Brotherton C, Brensinger C, Li H, Kappelman MD, et al. A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn\u2019s Disease. Gastroenterology. 2021;161:837-852.e9.","journal-title":"Gastroenterology"},{"key":"863_CR43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1475-2891-13-5","volume":"13","author":"BC Olendzki","year":"2014","unstructured":"Olendzki BC, Silverstein TD, Persuitte GM, Ma Y, Baldwin KR, Cave D. An anti-inflammatory diet as treatment for inflammatory bowel disease: a case series report. Nutr J. 2014;13:5.","journal-title":"Nutr J"},{"key":"863_CR44","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/ecco-jcc\/jju007","volume":"9","author":"J Langhorst","year":"2015","unstructured":"Langhorst J, Wulfert H, Lauche R, Klose P, Cramer H, Dobos GJ, et al. Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases. J Crohns Colitis. 2015;9:86\u2013106.","journal-title":"J Crohns Colitis"},{"key":"863_CR45","first-page":"87","volume":"14","author":"B Omer","year":"2007","unstructured":"Omer B, Krebs S, Omer H, Noor TO. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn\u2019s disease: a double-blind placebo-controlled study. Phytomedicine Int J Phytother Phytopharm. 2007;14:87\u201395.","journal-title":"Phytomedicine Int J Phytother Phytopharm"},{"key":"863_CR46","first-page":"305","volume":"17","author":"S Krebs","year":"2010","unstructured":"Krebs S, Omer TN, Omer B. Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn\u2019s disease - A controlled clinical trial. Phytomedicine Int J Phytother Phytopharm. 2010;17:305\u20139.","journal-title":"Phytomedicine Int J Phytother Phytopharm"},{"key":"863_CR47","first-page":"1502","volume":"4","author":"H Hanai","year":"2006","unstructured":"Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2006;4:1502\u20136.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"863_CR48","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1093\/ecco-jcc\/jjaa097","volume":"14","author":"K Sugimoto","year":"2020","unstructured":"Sugimoto K, Ikeya K, Bamba S, Andoh A, Yamasaki H, Mitsuyama K, et al. Highly Bioavailable Curcumin Derivative Ameliorates Crohn\u2019s Disease Symptoms: A Randomized, Double-Blind. Multicenter Study J Crohns Colitis. 2020;14:1693\u2013701.","journal-title":"Multicenter Study J Crohns Colitis"},{"key":"863_CR49","first-page":"484","volume":"26","author":"D Horta","year":"2020","unstructured":"Horta D, Lira A, Sanchez-Lloansi M, Villoria A, Teggiachi M, Garc\u00eda-Rojo D, et al. A Prospective Pilot Randomized Study: Electroacupuncture vs. Sham Procedure for the Treatment of Fatigue in Patients With Quiescent Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020;26:484\u201392.","journal-title":"Inflamm Bowel Dis."},{"key":"863_CR50","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000078151","volume":"69","author":"S Joos","year":"2004","unstructured":"Joos S, Brinkhaus B, Maluche C, Maupai N, Kohnen R, Kraehmer N, et al. Acupuncture and moxibustion in the treatment of active Crohn\u2019s disease: a randomized controlled study. Digestion. 2004;69:131\u20139.","journal-title":"Digestion"},{"key":"863_CR51","doi-asserted-by":"publisher","first-page":"11000","DOI":"10.3748\/wjg.v20.i31.11000","volume":"20","author":"C-H Bao","year":"2014","unstructured":"Bao C-H, Zhao J-M, Liu H-R, Lu Y, Zhu Y-F, Shi Y, et al. Randomized controlled trial: Moxibustion and acupuncture for the treatment of Crohn\u2019s disease. World J Gastroenterol WJG. 2014;20:11000\u201311.","journal-title":"World J Gastroenterol WJG"},{"key":"863_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101300","volume":"45","author":"C Bao","year":"2022","unstructured":"Bao C, Wu L, Wang D, Chen L, Jin X, Shi Y, et al. Acupuncture improves the symptoms, intestinal microbiota, and inflammation of patients with mild to moderate Crohn\u2019s disease: A randomized controlled trial. EClinicalMedicine. 2022;45: 101300.","journal-title":"EClinicalMedicine"},{"issue":"22","key":"863_CR53","first-page":"01061","volume":"S0016\u20135085","author":"X Hua","year":"2022","unstructured":"Hua X, Ungaro RC, Petrick LM, Chan AT, Porter CK, Khalili H, et al. Inflammatory Bowel Disease is Associated with Prediagnostic Perturbances in Metabolic Pathways. Gastroenterology. 2022;S0016\u20135085(22):01061\u20137.","journal-title":"Gastroenterology"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-023-00863-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11894-023-00863-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-023-00863-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T02:12:15Z","timestamp":1678759935000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11894-023-00863-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,8]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["863"],"URL":"https:\/\/doi.org\/10.1007\/s11894-023-00863-y","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,8]]},"assertion":[{"value":"16 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The corresponding author confirms on behalf of all authors that there have been no involvements that might raise the question of bias in the work reported or in the conclusions, implications, or opinions stated.JDC reports no conflict of interest.PK reports no conflict of interest.AA has served on scientific advisory boards for Abbvie, Takeda, Gilead, and Merck and has received research support from Pfizer.JFC reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Glaxo Smith Kline, Geneva, Iterative Scopes, Janssen Pharmaceuticals, Kaleido Biosciences, Landos, Otsuka, Pfizer, Prometheus, Sanofi, Takeda, TiGenix,; and hold stock options in Intestinal Biotech Development.MA reports no conflict of interest.RCU has served as an advisory board member or consultant for AbbVie, Bristol Myers Squibb, Janssen, Pfizer, and Takeda; research support from AbbVie, Boehringer Ingelheim, Eli Lilly, and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}